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BACKGROUND: Insulin-like growth factor-binding protein 7 (IGFBP7) is an abundant, selective and accessible biomarker of glioblastoma
multiforme (GBM) tumour vessels. In this study, an anti-IGFBP7 single-domain antibody (sdAb) was developed to target GBM vessels
for molecular imaging applications.
METHODS: Human GBM was modelled in mice by intracranial implantation of U87MG.EGFRvIII cells. An anti-IGFBP7 sdAb, isolated
from an immune llama library by panning, was assessed in vitro for its binding affinity using surface plasmon resonance and by ex vivo
immunobinding on mouse and human GBM tissue. Tumour targeting by Cy5.5-labelled anti-IGFBP7 sdAb as well as by anti-IGFBP7
sdAb conjugated to PEGylated Fe3O4 nanoparticles (NPs)-Cy5.5 were assessed in U87MG.EGFRvIII tumour-bearing mice in vivo
using optical imaging and in brain sections using fluorescent microscopy.
RESULTS: Surface plasmon resonance analyses revealed a medium affinity (KD¼40–50nM) binding of the anti-IGFBP7 sdAb to the
purified antigen. The anti-IGFBP7 sdAb also selectively bound to both mouse and human GBM vessels, but not normal brain vessels in
tissue sections. In vivo, intravenously injected anti-IGFBP7 sdAb-Cy5.5 bound to GBM vessels creating high imaging signal in the
intracranial tumour. Similarly, the anti-IGFBP7 sdAb-functionalised PEGylated Fe3O4 NP-Cy5.5 demonstrated enhanced tumour signal
compared with non-targeted NPs. Fluorescent microscopy confirmed the presence of anti-IGFBP7 sdAb and anti-IGFBP7 sdAb-
PEGylated Fe3O4 NPs selectively in GBM vessels.
CONCLUSIONS: Anti-IGFBP7 sdAbs are novel GBM vessel-targeting moieties suitable for molecular imaging.
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Glioblastoma multiforme (GBM) is a highly aggressive tumour
with distinct histopathalogical features, including high proliferation,
necrosis and considerable neo-vascularisation (i.e., angiogenesis),
leading to vessels that exhibit morphological abnormalities and
‘leakiness’ (Vajkoczy and Menger, 2000). It is generally accepted that
the degree of angiogenesis is correlated to the malignancy of the
tumour (Daumas-Duport et al, 1997a,b). Therefore, assessment of
the rate of tumour angiogenesis using specific biomarkers is
potentially useful clinical information for determining the severity
of the disease and selecting appropriate treatment modality.
Currently, there is a limited number of targeting ligands that
have been utilised to non-invasively assess the degree of tumour
angiogenesis. For GBM, these targeting moieties include the
endogenous protein, vascular endothelial growth factor (VEGF),
which binds to the vascular endothelial growth factor receptor 2
(VEGFR2) (Olsson et al, 2006), and Arg–Gly–Asp (RGD)-
containing peptides that interact with endothelial cell adhesion
molecules, such as avb3 and avb5 integrins (Varner and Cheresh
1996). Although these targeting moieties have shown promise in
pre-clinical PET studies, some drawbacks, including hetero-
geneous target expression and nonspecific targeting to non-tumour
vessels (Weibo et al, 2006; Schnell et al, 2009), remain unresolved.
In our previous transcriptomic analyses of the laser-capture
microdissected GBM vessels, the insulin-like growth factor-
binding protein-7 (IGFBP7) was discovered as a highly upregulated
selective biomarker of GBM vessels (Pen et al, 2007).
The IGFBP7, also known as IGFBP-related protein 1, mac25,
TAF and angiomodulin, is a 31kDa secreted protein that shares
structural homology with a family of IGFBP-related proteins,
which includes IGFBP1-6 (Kim et al, 1997). In contrast to IGFBP1-
6 that displays high affinity for insulin-like growth factor (IGF),
IGFBP7 is classified in the family subgroup showing low affinity
for IGF (Kim et al, 1997). Several studies demonstrated that
IGFBP7 is overexpressed in tumour blood vessels with little or no
expression in normal blood vessels (Akaogi et al, 1996; St Croix
et al, 2000; Pen et al, 2007), nor in the non-malignant angiogenic
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splacental tissues (van Beijnum et al, 2006). IGFBP7 accumulates in
the basement membrane of the tumour endothelium, where it can
bind to collagen type II, IV and V, heparin sulphate proteoglycans
and other cytokines (Nagakubo et al, 2003). Insights into
mechanisms of IGFBP7 expression in the glioblastoma environ-
ment have come from in vitro experiments, which demonstrated
that TGF-b1 secreted from glioblastoma tumour cells stimulate
IGFBP7 production in human brain endothelial cells (HBECs) (Pen
et al, 2008). IGFBP7 appears to increase the formation of capillary-
like tubes by HBEC, suggesting a pro-angiogenic activity (Pen et al,
2007). Therefore, IGFBP7 is a selective and abundantly expressed
biomarker of human GBM vessels that could be exploited for
selective targeting of tumour vessels for imaging and therapeutic
applications.
In this study, a llama anti-IGFBP7 single-domain antibody
(sdAb) was developed and assessed in a mouse model of GBM for
its ability to detect tumour vessels after in vivo administration. The
sdAbs are small (13–15kD) targeting molecules derived from
the variable regions of heavy-chain antibodies from the camelid
species (Hamers-Casterman et al, 1993). In contrast to IgG
antibodies, sdAbs have fast pharmacokinetics due to small size,
low nanomolar affinities when isolated from an immune library
(Arbabi Ghahroudi et al, 1997) and can be easily engineered into
a variety of antibody constructs (Conrath et al, 2001; Zhang
et al, 2004). The anti-IGFBP7 sdAb developed in this study was
demonstrated to bind specifically to both human and mouse
GBM vessels in brain tissue sections and to tumour vessels after
systemic injection in a mouse model of orthotopic glioblastoma.
In addition, anti-IGFBP7 sdAb was shown to target PEGylated
superparamagnetic nanoparticles (NPs) (T2-reducing MRI con-
trast agents) functionalised with the near-infrared probe Cy5.5 for
optical detection, to the vessels of orthotopic brain tumour in
mice, creating high tumour-contralateral side signal-to-noise ratio
and selective tumour accumulation compared with other organs in
prospective in vivo optical imaging. The results suggest that anti-
IGFBP7 sdAb can be used to target appropriate contrast agents to
abnormal tumour vasculature for non-invasive assessment of brain
tumour angiogenesis using various imaging modalities.
METHODS
Isolation of anti-IGFBP7-specific sdAbs from a llama
immune phage display library
Recombinant human IGFBP7 protein was produced as described
previously (Pen et al, 2008). A male llama (Lama glama) was
injected subcutaneously with 100, 75, 75, 50 and 50mg IGFBP7
recombinant human protein on days 1, 21, 36, 50 and 64,
respectively. Complete Freund’s adjuvant (Sigma, Oakville, ON,
Canada) was used for the primary immunisation and incomplete
Freund’s adjuvant was used for immunisations 2–4. Adjuvant was
not used for the final immunisation. Total RNA was isolated from
2 10
7 leukocytes using a QIAamp RNA Blood Mini Kit (Qiagen,
Mississauga, ON, Canada). cDNA was synthesised using pd(N)6
primers. Three different sense primers (called J0 corresponding
to the 50-end of IgG), including MJ1 (50-GCCCAGCCGGC
CATGGCCSMKGTGCAGCTGGTGGAKTCTGGGGGA-30), MJ2 (50-CA
GCCGGCCATGGCCCAGGTAAAGCTGGAGGAGTCTGGGGGA-30)
and MJ3 (50-GCCCAGCCGGCCATGGCCCAGGCTCAGGTACAGCT
GGTGGAGTCT-30), and two anti-sense primers, corresponding to
the CH2 domain DNA sequence, CH2( 5 0-CGCCATCAAGGTACC
AGTTGA-30) and CH2b3( 5 0-GGGGTACCTGTCATCCACGGACCA
GCTGA-30), were used to amplify the VH-CH1-hinge-CH2 region of
conventional IgG or VHH-hinge-CH2. Amplified products of
B600bp from the primer combination J0-CH2 were extracted
from a 1% agarose gel and the amplified products from primers
J0-CH2b3 were PCR purified. In a second PCR, the two primers of
MJ7BACK (50-CATGTGTAGACTCGCGGCCCAGCCGGCCATGGC
C-30) and MJ8FOR (50-CATGTGTAGATTCCTGGCCGGCCTGGCC
TGAGGAGACGGTGACCTGG-30) were used to introduce SfiI
restriction sites and to amplify the final sdAb fragments from
the combined J0-CH2 and J0-CH2b3 amplified products. The final
PCR product was digested with SfiI and ligated into pMED1
(Arbabi-Ghahroudi et al, 2009), which was previously digested
with the same restriction enzymes, and transformed into E. coli
TG1 (New England Biolabs, Pickering, ON, Canada) by electro-
poration. A library size of 2 10
7 was constructed and its
complexity was determined by sequencing B30 randomly picked
up colonies. Phage antibodies were rescued from the library with
helper phage M13KO7 (New England Biolabs) and purified as
described in Doyle et al (2008).
The llama immune phage display library was panned against
purified IGFBP7. The VHHs recognising IGFBP7 were enriched by
four consecutive rounds of in vitro selection. After each selection,
the IGFBP7-specific phages were eluted with 100mM triethylamine
(pH 10.0) and immediately neutralised with 1 M Tris-HCl, pH 7.5.
Exponentially growing TG1 cells were infected with the eluted
phages followed by superinfection with M13KO7 helper phages.
Finally, phages were amplified in a 50-ml baffled flask (2YT-
Amp-Kan) overnight. After four rounds of panning, the eluted
phages were used to infect exponentially growing E. coli TG1 cells.
Individual colonies were grown, phage-rescued, and amplified
phages were used in phage ELISA experiment.
For phage ELISA, wells of a 96-well plate were coated overnight
with 5mgml
–1 IGFBP7 protein and then blocked with 1% casein
for 2h at 371C. Phage (100ml) from individual clones were added to
the pre-blocked wells and incubated for 1h. Phage ELISA was
performed using the Detection Module Recombinant Phage Anti-
body System (GE Healthcare, Baie d’Urfe, QC, Canada), and positive
phage clones were sequenced. Sequencing results showed that the
panning enriched mainly two clones with distinct sequences.
Expression of anti-IGFBP7 sdAbs
DNA encoding the two positive clones was cloned into the BbsI and
BamHI sites of a periplasmic expression vector, pSJF2, which
added a c-Myc detection tag and a 5 His purification tag at the
C-terminus of the sdAbs. Anti-IGFBP7 sdAbs were expressed
periplasmically and purified by IMAC as described previously
(Abulrob et al, 2005).
SPR analysis
Anti-IGFBP7 sdAbs were evaluated by surface plasmon reson-
ance (SPR) using a Biacore 3000 (GE Healthcare) as described
previously (Iqbal et al, 2010). Briefly, B1400RU of recombi-
nant human IGFBP7 (R&D Systems, Minneapolis, MN, USA)
and 900RU of ovalbumin (Sigma) as a reference protein were
immobilised on a CM5 sensor chip using the amine-coupling kit
supplied by the manufacturer. All binding studies were carried
out at 251Ci n1 0 m M HEPES, pH 7.4 containing 150mM NaCl,
3m M EDTA and 0.005% surfactant P20. The flow rate used was
40mlmin
–1. The IGFBP7 surface was regenerated thorough
washing with the running buffer. Data were analysed with
BIAevaluation 4.1 software (GE Healthcare).
Orthotopic brain tumour model
All animal procedures were approved by the NRC-IBS Animal Care
Committee and were in strict compliance with the recommenda-
tions of the Canadian Council of Animal Care. Brain tumours
were generated in nude CD-1 mice (male, 6–8 weeks old)
by intracranial implantation of tumour-generating glioblastoma
cell line, U87MG.EGFRvIII, carrying deletion mutant of EGFR
(EGFRvIII) cells as described previously (Iqbal et al, 2010).
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Frozen human brain tumour tissues were obtained from Dr
Garnette Sutherland (Foothills Hospital, Calgary, AB, Canada) with
approval by both Foothills Hospital and NRC Research Ethics
Boards. Human and mouse brain tissues were sectioned on a
cryostat (Jung CM3000; Leica, Richmond Hill, ON, Canada) at
10mm thickness, and then mounted on Superfrost Plus microscope
slides (Fisher Scientific, Nepean, ON, Canada).
Immunohistochemisty
Frozen human or mouse brain tumour tissue sections were fixed in
methanol at room temperature (RT). Slides were rinsed with 0.2 M
PBS (pH 7.3), followed by blocking with 5% goat serum containing
0.1% Triton-X in PBS. Slides were then incubated with anti-
IGFBP7 sdAb 4.43 (1:100 of a 1mgml
–1 solution) for 3h at RT,
washed and then incubated with mouse monoclonal anti-c-myc
primary (1:500) antibody for 1h. Sections were washed five times
before incubation with secondary antibody, goat anti-mouse alexa
647 (1:500; Molecular Probes, Eugene, OR, USA) for 1h at RT. To
stain blood vessels, human GBM tissue slides were incubated with
Ulex europaeus I agglutinin (ULEX) (1:20; Vector Laboratories,
Burlington, ON, Canada) for 3min at RT, whereas mouse GBM
tumour sections were incubated with rat anti-mouse CD31 primary
antibody for 1h at RT followed by goat anti-rat alexa 568 secondary
antibody (1:300) for 1h at RT. All slides were then washed and
then cover slipped using DAKO fluorescent mounting (Dako,
Burlington, ON, Canada) media containing Hoechst (1:1000;
Sigma). In control slides, the anti-IGFBP7 sdAb was omitted.
Synthesis of iron oxide PEGylated NPs
To synthesise 10nm Fe3O4 NPs, 2mmol of iron acetylacetonate,
10mmol of 1, 2-hexadecanediol, 6mmol of oleic acid, 6mmol of
oleylamine and 20ml of phenyl ether were mixed and magnetically
stirred in a three-neck 100ml glass flask under nitrogen
protection. The mixture was heated to 2001C for 30min and, the
temperature then was raised to 2651C and maintained for another
30min. The mixture was then cooled to RT and ethanol was added
to precipitate the product and the solid phase was obtained by
centrifugation. The final product, 10nm NPs as determined by
transmission electron microscopy, was separated and purified
from non-reacted residues by dissolving/precipitating cycles using
a hexane/ethanol solvent pair. The final solution was prepared by
re-dispersing the Fe3O4 wet solid into hexane. The powder form
was obtained by drying the wet solid in vacuum. For PEGylation of
the NPs, 40mg of magnetic NPs were dissolved into 50ml hexane
and 1ml oleylamine. The mixture was sonicated until the NPs were
totally solubilised. The pH was set at 9 and 100mg carboxy-amino-
PEG (MW: 3000Da) (Creative PEGs works, Winston Salem, NC,
USA) was added and heated to reflux for 2h. The supernatant was
removed and a grey solid was washed three to five times with
hexane and dried under nitrogen.
Bioconjugation of sdAbs to PEGylated NPs
PEGylated NPs were solubilised in PBS buffer (PBS, 0.5mM EDTA,
pH 7.4) such that the final concentration of iron was 1mgFeml
–1.
Cy5.5-NHS ester was added to the NP solution at 50-fold molar excess
and reacted for 1h at RT. Unreacted dye was removed using 50kDa
Amicon ultra centrifugal units (Millipore, Billerica, MA, USA).
A 500-fold molar excess anti-IGFBP7 sdAb 4.43 was reconsti-
tuted in MES buffer (0.1 M MES, 0.5 M NaCl, pH 5.5). To introduce
NHS-ester functionality on the sdAb, Sulfo-NHS and EDC were
added at 180- and 70-fold molar excess, respectively, and reacted
for 30min at RT. Subsequently, EDC was removed by centrifuga-
tion using 3kDa Amicon columns. Cy5.5-labelled PEGylated NPs
were added to the antibody solution and reacted at RT for 4–6h
while mixing. Unreacted sdAbs were removed by purification in
100kDa Amicon columns. Anti-IGFBP7 sdAb-NP-Cy5.5 formula-
tion was resuspended in PBS (0.5mM EDTA, pH 7.4). Protein
absorbance at 280nm, after subtracting for background absor-
bance from PEGylated NPs alone, indicated B50 sdAbs attached
per PEGylated NP. Dynamic light scattering on both PEGylated
NPs and anti-IGFBP7 sdAb-PEGylated NPs was done using a
Zetasizer nano (Malvern Instruments, Worcestershire, UK). The
dynamic light scattering experiments were carried out at 231Co n
samples dispersed (1:100) in milliQ water. The following
parameters were used for data analysis to reflect solid particles
in water: material refractive index of 1.59, a dispersant refractive
index of 1.33 and a dispersant viscosity of 0.9308. Size distribution
was determined by intensity-weighted data analysis.
Pharmacokinetic analysis
Non-targeted Cy5.5-labelled PEGylated NPs were injected via tail
vein in normal CD-1 mice. Blood samples of 25ml were collected by
creating a small nick in the tail vein followed by collection of blood
in a heparanised tube. Blood samples were collected at multiple
time points at 5min, 30min, 1, 1.5, 2, 4, 24 and 48h after injection.
Samples were analysed for labelled NPs using a fluorescent plate
reader with excitation at 670nm and emission at 690nm and
compared with a standard curve of a range of concentrations of the
labelled NPs diluted in blood. Pharmacokinetic parameters were
calculated with a two-compartment, IV-bolus model using the
WinNonlin pharmacokinetic software 5.2 (Pharsight Corporation,
Mountain View, CA, USA).
In vivo near-infrared optical imaging
Anti-IGFBP7 sdAb 4.43 was labelled with Cy5.5 succinimidyl ester
using methods recommended by the manufacturer (GE Health-
care). Labelling was optimised to achieve a dye/antibody ratio of
one. Anti-IGFBP7 sdAb-Cy5.5 (50mg for IGFBP7sdAb 4.43 or 50mg
negative control (NC) sdAb) were injected via the tail vein in mice
bearing 10-day-old U87MG.EGFRvIII brain tumours. Additionally,
a competition experiment was also performed in which 100-fold
excess concentration of unlabelled anti-IGFBP7 sdAb was injected
intravenously 10min before the injection of 50mg IGFBP7sdAb-
Cy5.5. In other experiments brain tumour-bearing mice were
injected with anti-IGFBP7-sdAb NP-Cy5.5 or non-targeted NP-
Cy5.5 (10mgFe per kg body weight) via the tail vein. Animals were
subjected to in vivo imaging studies using a small-animal time-
domain eXplore Optix MX2 pre-clinical imager (Advanced
Research Technologies, Montreal, QC, Canada) as described
previously (Abulrob et al, 2007, 2008). Average fluorescence
concentration data from ROIs placed around the tumour region
were subsequently analysed using the OptiView software package
(Advanced Research Technologies). At the end of each experiment,
mice were injected with 40mg of fluorescein-labelled tomato lectin,
10min before killing to stain blood vessels. Animals were then
perfused with heparanised saline and organs and brain tumours
were excised and imaged ex vivo. Ex vivo organs were analysed by
placing an ROI around each organ and determining the total
fluorescence concentration per gram tissue.
Fluorescent microscopy
Coronal sections (50mm) were produced using a Vibratome
sectioning instrument (Ted Pella, Redding, CA, USA). Tissue
sections were mounted on Superfrost Plus microscope slides
(Fisher Scientific, Nepean, ON, Canada) using mounting media
containing 2mgml
–1 Hoescht nuclei stain (Sigma). Sections were
then visualised under an Olympus 1X 81 inverted motorised
microscopes (Olympus, Markham, ON, Canada). InVivo and
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used to acquire and analyse images. Some sections were
alternatively stained with hematoxylin (0.1% hematoxylin, 5%
alum, 0.02% sodium iodate, 0.1% citric acid) and 1% eosin Y.
Statistical analysis
All data are reported as mean±s.e.m. and the differences between
groups were determined using two-way ANOVA followed by the
Bonferoni post hoc test. Differences greater than Po0.05 were
considered significant.
RESULTS
Binding by SPR
Based on phage ELISA results (data not shown), two clones showed
binding to IGFBP7, clones 4.43 and 4.46. In SPR analyses, clone
4.43 showed strong binding to antigen but the affinity of clone 4.46
for IGFBP7 was in the low micromolar range (data not shown). As
a result, only clone 4.43 was selected for further analysis both
in vitro and in vivo studies. The binding data for 25nM 4.43
(Figure 1A) fit quite well to a 1:1 model, giving a ka of 6.6 
10
4ms
 1,akd of 1.3 10
 3s
 1 and a KD of 20nM. However, at
higher 4.43 concentrations the 1:1 fitting was poor with the
dissociation phases being clearly biphasic (Figure 1A). Never-
theless, the equilibrium binding data showed good fitting to a
steady state affinity model (Figure 1B) and gave a linear Scatchard
plot (Figure 1C) from which KD’s of 40 and 50nM, respectively,
were derived. Inexplicably, the observed Rmax for the equilibrium
data was several fold higher that the theoretical Rmax for a 1:1
interaction in which monovalent sdAb binds to an immobilised
antigen without repeating sequences, an observation that may
compromise the kinetic and affinity constant calculations.
Immunofluorescence staining of mouse and human GBM
tissues with anti-IGFBP7 sdAb
The ability of anti-IGFBP7 sdAb to detect IGFBP7 expression in
mouse and human GBM tissue was evaluated by immunofluores-
cence (Figure 2). In brain sections of GBM-bearing mice, IGFBP7
immunoreactivity detected by anti-IGFBP7 sdAb (clone 4.43) was
enhanced and detected specifically in the tumours (Figure 2A), but
not in normal brain (Figure 2B), and colocalised with the immuno-
reactivity against the vascular antigen, CD31 (Figure 2A). No
IGFBP7 expression was observed in non-tumour brain vessels or in
non-vascular cells. In surgically removed human GBM tissue,
IGFBP7 immunoreactivity (Figure 2C, middle panel) colocalised
with highly abnormal tumour vasculature stained with Ulex
europeaus agglutinin I (UEA I) (Figure 2C, right panel), shown
previously to selectively bind to carbohydrates of human brain
vessels (Holthofer et al, 1982). These results indicate that anti-
IGFBP7 sdAb detects its target, IGFBP7, in both mouse and human
GBM tissue sections ex vivo. This analysis confirms our previous
observation of a selective vascular upregulation of IGFBP7 in
human GBM (Pen et al, 2007) and demonstrates that mouse
vessels ingrowing into orthotopically implanted human GBM
(U87MG-EGFRvIII) are selectively induced by the tumour micro-
environment to overexpress IGFBP7. This mouse model is thus
suitable for in vivo assessment of tumour targeting/imaging using
anti-IGFBP7 sdAb.
In vivo biodistribution of anti-IGFBP7 sdAbs
The in vivo and ex vivo biodistribution analyses of the systemically
injected anti-IGFBP7 sdAb ‘tagged’ with the near-infrared dye
Cy5.5 alone or in combination with the 100-fold excess of
unlabelled anti-IGFBP7-sdAb or NC sdAb-Cy5.5 were performed
in mice bearing a 10-day-old U87MG.EGFRvIII orthotopic GBM
tumour using prospective in vivo optical imaging (Figure 3A).
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Figure 1 Protein sequence and surface plasmon resonance analysis of the anti-IGFBP7 sdAb 4.43. (A) Protein sequence of anti-IGFBP7 sdAb 4.43; CDR1,
CDR2 and CDR3 are underlined. (B) Sensogram overlay showing 4.43 monomer binding to immobilised IGFBP7 at concentrations of 25, 25, 50, 50, 75, 75,
100 and 200nM.( C) Fitting of equilibrium binding data to a steady-state affinity model. (D) Scatchard plots of the equilibrium binding data.
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as 10min after injection (Figure 3A, upper panels; Figure 3C),
with high signal in the tumour persisting up to 24h after injec-
tion. In contrast, brain tumour signal in vivo was reduced at 4 and
24h when animals were co-injected with the excess unlabelled
anti-IGFBP7 sdAb (Figure 3A, middle panels; Figure 3B). NC
sdAb-Cy5.5 (Figure 3A, lower panels; Figure 3B) was barely
detectable in the brain tumour at any time. At 24h after injection,
brain tumour signal for the anti-IGFBP7 sdAb-Cy5.5 was
three- and six-fold higher compared with competitively blocked
anti-IGFBP7 sdAb-Cy5.5 and NC sdAb-Cy5.5, respectively
(Figure 3B). As sdAbs have a blood half-lives in the range of
20–30min and are completely cleared from the blood within
the first few hours (Iqbal et al, 2010) after injection, the high
tumour signal detected at 4 and 24h with anti-IGFBP7 sdAb-Cy5.5,
which was competitively attenuated in the presence of the excess of
unlabelled anti-IGFBP7 sdAb, indicates retention of the antibody
in the tumour due to its binding to the tumour-expressed antigen.
Organs (liver, kidney, spleen, lung, heart, brain and muscle)
and extracted tumour biodistribution (Figure 3C) assessed by
ex-vivo organ imaging 24h after injection confirmed the selective
brain tumour targeting of anti-IGFBP7 sdAb, but not NC sdAb.
Similar to the in vivo data, the ex-vivo data at 24h demonstrated a
three- and six-fold increase in brain tumour signal for the anti-
IGFBP7 sdAb compared with the competitively blocked anti-
IGFBP7 sdAb-Cy5.5 and NC sdAb-Cy5.5, respectively (Figure 3D).
No optical signals were detected in the contralateral normal
brain. Fluorescence lifetime analysis confirmed that 90% of the
signal in the brain tumour originated from sdAb linked to Cy5.5
(t¼2.1ns), in contrast to a virtual absence of the free Cy5.5
fluorescence lifetime (t¼1.1ns) (data not shown). Both sdAbs
(anti-IGFBP7 and NC) gave a high kidney signal, which is the main
elimination route for sdAbs, whose size of 13kD is below kidney
filtration cutoff.
Fluorescent microscopy confirmation of injected
anti-IGFBP7 sdAb-Cy5.5 in brain tumours
U87MG brain tumours grew in a spherical shape that was easily
distinguishable from the surrounding health brain, when visua-
lised by hematoxylin and eosin staining (Figure 4A). At higher
magnification, hematoxylin and eosin staining clearly illustrates
the demarcation of the increased cellularity of the tumour vs the
normal brain regions (Figure 4A, right panel).
At the end of imaging protocol (24h after injection), brain
sections were analysed by fluorescent microscopy to examine
Figure 2 Representative immunofluorescence images demonstrating IGFBP7 immunoreactivity detected with the anti-IGFBP7 sdAb 4.43 in tissue sections
of the (A) mouse orthotopic GBM, (B) contralateral healthy mouse brain and (C) human GBM. IGFBP7 immunoreactivity is shown in red (middle panels);
the staining for the endothelium-specific markers, CD31 and UEA1, for mouse and human tissues, respectively, is shown in green (right panels) and cell
nuclei stained with DAPI are shown in blue in overlay images (left panels).
Figure 3 In vivo optical imaging of mice bearing orthotopic glioblastoma tumours after intravenous (i.v.) administration of anti-IGFBP7 sdAb labelled with
the near-infrared fluorescent probe, Cy5.5. (A) Dorsal whole body in vivo optical images of mice bearing U87MG.EGFRvIII brain tumours at indicated time
points after i.v. injection of 50mg of either anti-IGFBP7 sdAb-Cy5.5 (upper panels), 100  unlabelled anti-IGFBP7 sdAb followed by anti-IGFBP7 sdAb-Cy5.5
(competitive block, middle panels) or NC sdAb-Cy5.5 (lower panels) (arrows indicate the location of the brain tumour). (B) Graph illustrating changes in the
average fluorescence concentration determined from an ROI in the brain tumour region in vivo at indicated times after the i.v. injection of sdAbs-Cy5.5.
(C) Optical images of organs ex vivo and dissected brain tumours 24h after injection of sdAbs-Cy5.5 (D) Graph illustrating the total fluorescence
concentration per gram tissue in various organs and dissected tumours imaged ex vivo 24h after the injection of sdAbs-Cy5.5. In B and D, the data are
expressed as mean±s.e.m. for n¼5 animals. *Indicates significant difference between anti-IGFBP7 sdAb and both competitively blocked anti-IGFBP7 sdAb
and NC sdAb (Po0.01).
#Indicates significant difference between competitively blocked anti-IGFBP7-sdAb and NC sdAb (Po0.05).
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slocalisation of injected Cy5.5-labelled sdAbs. In contrast to NC-
sdAb-Cy5.5 fluorescence, which could not be detected in either
tumour or healthy brain tissue sections (data not shown), anti-
IGFBP7 sdAb-Cy5.5 fluorescence (red) was selectively localised
in brain tumour vessels stained with injected lectin (Figure 4B),
but not in healthy brain tissue vessels (Figure 4C). In lower-
magnification images the fluorescence of injected anti-IGFBP7
sdAb-Cy5.5 was present throughout the tumour in virtually all
vessels (Figure 4D). These results confirm that the increased
tumour optical signal observed in in vivo optical imaging resulted
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sfrom the selective ‘homing’ of anti-IGFBP7 sdAb to abnormal,
IGFBP-expressing brain tumour vessels.
Characterisation of iron oxide NPs
The Fe3O4-based NPs (10nm core) were monodisperse and uniform,
as shown in representative transmission electron microscopy images
in Figure 5A. The NPs were coated with hundreds of primary amine-
PEG3000 molecules to serve as attachment moieties for Cy5.5 and
multiple sdAbs (Figure 5B). The presence of amine-PEG3000 was
confirmed using fluorescamine, a non-fluorescent agent that
fluoresces when it reacts with primary amines (Udenfriend et al,
1972) (data not shown). PEGylation produced NPs that were stable
and water soluble. Dynamic light scattering of the PEGylated NP
revealed a hydrodynamic diameter of 99nm with a polydispersity
index (PDI) of 0.2. PDI is a measure of particle size distribution and
values o0.2 can be considered to be narrowly distributed.
Bioconjugation of sdAb to the PEGylated NP increased the average
particle size to 124nm, while maintaining a PDI of 0.18. In vivo,
PEGylation resulted in NPs with a circulation half-life of approxi-
mately 24h (Figure 5C).
Biodistribution and tumour targeting of
anti-IGFBP7sdAb-PEGylated NPs-Cy5.5 in vivo
The biodistribution of anti-IGFBP7 sdAb-PEGylated NPs-Cy5.5
and non-targeted PEGylated NPs-Cy5.5 after systemic injection
was examined by in vivo imaging in mice bearing 10-day-old
orthotopic glioblastoma tumours. Whereas a progressive increase
in optical signal peaking at 24h after injection was observed in the
brain tumour region in animals injected with the anti-IFGBP7
sdAb-PEGylated NPs-Cy5.5 (Figure 6A, upper panels, Figure 6C),
no specific accumulation of non-targeted NPs was observed in the
head ROI (Figure 6A, bottom panels; Figure 6C. Anti-IGFBP7
sdAb-PEGylated NPs-Cy5.5 fluorescence signal in the tumour
region diminished after 24h (Figure 6A, upper panels, Figure 6C).
However, when the signal-to-noise ratio was determined by
dividing the average fluorescence concentration values in the
tumour region with that in the contralateral healthy brain region,
a steady increase of the signal, peaking at 72h was observed in
the tumour region (data not shown). The whole-body scans
(Figure 6B, upper panels) and ex vivo organ imaging (Figure 6B;
bottom panels; Figure 6D) at 72h after injection demonstrated that
Figure 4 Fluorescent and light microscopic images of mouse orthotopic GBM tumour sections obtained 24h after intravenous (i.v.) injection of 100mg
anti-IGFBP7 sdAb-Cy5.5. (A) Sections of brain tumour stained with hematoxylin and eosin staining showing brain tumour boundaries from the ipsilatelar
healthy brain tissue (left panel, low magnification; right panel, high magnification). Higher magnification fluorescent images of tumour centre (B) and
contralateral healthy brain region (C) showing colocalisation of the systemically injected anti-IGFBP7 sdAb-Cy5.5 (red; middle panels) and brain vessels
stained with the 40mg fluorescein tomato lectin (green; right panels) injected i.v. 10min before killing, and their composite overlay images with nuclei stained
with DAPI (blue; left panels). Scale bar: 50mm. (D) Lower magnification image of the tumour and normal brain illustrating that injected anti-IGFBP7 sdAb-
Cy5.5 (red) decorates selectively a majority of tumour vessels 24h after i.v. injection. Scale bar: 100mm.
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sthe brain tumour signal of anti-IGFBP7 sdAb-PEGylated NPs-
Cy5.5 is the highest compared with all other organs. Similarly,
at 72h, ex vivo-measured fluorescence in the brain was five-fold
higher in mice injected with anti-IGFBP7sdAb-targeted compared
with non-targeted PEGylated NPs.
Fluorescent microscopy confirmation of injected
anti-IGFBP7 sdAb-PEGylated NPs-Cy5.5 in brain tumours
Sections from GBM tumour-bearing mice receiving anti-IGFBP7
sdAb-PEGylated NPs-Cy5.5 demonstrated Cy5.5 fluorescence (red)
in the tumour region, colocalising with the tomato-lectin-stained
vessels (green) (Figure 7A) compared with virtual absence of
Cy5.5 fluorescence in tumour sections from animals injected with
non-targeted PEGylated NPs-Cy5.5 (Figure 7B). The contralateral
healthy brain did not show any measurable Cy5.5 signal in animals
injected with either anti-IGFBP7 sdAb-targeted (Figure 7C) or
non-targeted PEGylated NPs-Cy5.5 (data not shown).
DISCUSSION
The aim of the study was to generate novel targeting moieties
against brain tumour vasculature useful in brain tumour imaging.
IGFBP7 was confirmed in this study as a selective vascular target
that is overexpressed in both human GBM and in an orthotopic
mouse model of GBM. The anti-IGFBP7 sdAb was then raised
and assessed for use as molecular imaging agent/diagnostic for
GBM. The sdAb format was chosen due to its small size (15kDa),
fast clearance kinetics and moderate affinity for its targets,
characteristics advantageous in molecular imaging applications
(Lin et al, 2010). After panning an immunised library for binders,
an sdAb with moderate affinity (Kd in low nanomolar range) for
the IGFBP7 target was selected. In contrast to control sdAb, anti-
IGFBP7 sdAb fluorescently tagged for detection was found to bind
specifically to both human and mouse GBM tumour vessels ex vivo
and to brain tumour vessels in mice after injection in vivo, creating
high signal-to-noise ratio in orthotopic brain tumours easily
detectable by in vivo optical imaging. In addition, we show that the
anti-IGFBP7 sdAb could be utilised to target bimodal optical-MRI
contrast agent based on Fe3O4 PEGylated NPs labelled with Cy5.5.
Using in vivo optical imaging, brain tumour selective targeting in
mice was demonstrated for the anti-IGFBP7 sdAb-PEGylated-NPs-
Cy5.5, in contrast to a non-targeted-PEGylated-NPs-Cy5.5. The
results of the study suggest that anti-IGFBP7 sdAbs and anti-
IGFBP7 sdAb-PEGylated-NPs are both promising molecular
imaging agents for targeting brain tumour vessels with potential
for clinical translation.
The VEGFR2 is another target highly expressed on tumour
endothelial cells (Ferrara 2004) and exploited for developing
molecular imaging strategies for tumours. The targeting moiety,
64Cu-labelled vascular endothelial growth factor 121 (VEGF121) has
been developed for non-invasive PET imaging of VEGFR expres-
sion in small animals (Cai et al, 2006). Similar to anti-IGFBP7
sdAb, VEGF121 has a low nanomolar affinity and fast clearance
from the body due to its small size (25kDa) (Goncalves et al,
2005). In pre-clinical PET studies, VEGFR expression was shown to
be heterogeneous in GBM xenografts depending on the size of the
tumour (Cai et al, 2006). Another well-studied marker of GBM
tumour vessels explored for non-invasive imaging of tumour
vessels (Schottelius et al, 2009) is the avb3 integrin, against which
several RGD containing peptide binders were developed. In a
recent study in which [
18F]galacto-RGD peptide was used for PET
imaging assessment of avb3 integrin expression in patients with
GBM (Schnell et al, 2009), it was demonstrated that GBMs had very
heterogeneous tracer uptake, which, however, correlated well with
immunohistochemically determined avb3 expression. In contrast
to IGFBP7, avb3 integrin expression is also associated with non-
tumour angiogenic vessels and tumour cells (Cairns et al, 2003).
Anti-IGFBP7 sdAb have advantages compared with other pre-
dominantly peptide-based strategies, including high specificity to
the target, while retaining appropriate pharmacokinetic character-
istics for imaging applications, including PET; further studies
comparing anti-IGFBP7 sdAb with other brain tumour-vessel
targeting molecular imaging agents in PET studies are warranted.
In addition to GBMs, high vascular expression of IGFBP7 has been
shown in some peripheral tumours, including oesophagus, lung
and stomach cancers (Akaogi et al, 1996).
An added benefit of the anti-IGFBP7 sdAb-targeted bimodal
NPs developed in this study is the possibility of using MRI to
Cy5.5 PEGylated Fe3O4-10 nm
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Figure 5 (A) Representative transmission electron microscopy image of NPs at two magnifications. (B) Schematic diagram of the anti-IGFBP7 sdAb
conjugated to a PEGylated Fe3O4 NP and labelled with Cy5.5. (C) Graph of 10nm core PEGylated NP-Cy5.5 concentration in serum over time, fitted to a
two-compartment, IV-bolus model (WinNonLin 5.2).
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snon-invasively assess tumour angiogenesis. MRI is a widely
available modality with high spatial resolution for in vivo imaging,
whereas optical imaging currently remains a useful pre-clinical
tool. In this study, anti-IGFBP7 sdAb PEGylated NPs displayed
specific targeting to brain tumours compared with non-targeted
PEGylated NPs. The anti-IGFBP7 sdAb-targeted PEGylated NPs
also displayed a greater level of targeting compared with the anti-
IGFBP7 sdAb alone. This effect may be attributed to an increased
avidity for the IGFBP7 target, as a result of the multivalent nature
of the NPs (i.e., multiple sdAbs bound to each NP). Although not
analysed in this study, many reports have described an increase in
binding avidity (up to four orders of magnitude) for multivalent
targeted NPs (Hong et al, 2007; Iqbal et al, 2010; Tassa et al, 2010).
An additional feature of PEGylated NPs is their longer circulation
half-life (days) vs non-PEGylated NPs (hours) or sdAbs alone
(mins). The level of PEGylation on the NPs can be adjusted and the
pharmacokinetics of the NPs can be further tailored (Lim et al,
2008). For clinical use, a targeted NP that can achieve a high signal
to background ratio, followed by complete elimination from the
body would be ideal.
Despite many therapeutic advances in the field, most patients
with GBM still have poor prognosis, with a life expectancy of
12–15 months (Strupp et al, 2005). In contrast, low-grade gliomas
(WHO grade II) show little or no neo-vascularisation and much
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Figure 6 In vivo optical imaging of the biodistribution of non-targeted and anti-IGFBP7 sdAb-targeted Fe3O4 nanoparticles labelled with Cy5.5 injected at
10mgFekg
–1intravenous (i.v.) in mice bearing orthotopic glioblastoma tumours. (A) In vivo images of the head indicated time points after the injection of
anti-IGFBP7-targeted (upper panels) and non-targeted (lower panels) NPs. (B) In vivo optical images of whole animal body (upper panels) 72h after i.v.
injection of anti-IGFBP7-targeted and non-targeted NPs and corresponding ex vivo organ images after animal killing by perfusion (bottom panels). (C) Graph
showing changes of the average fluorescence concentration in the brain tumour region in vivo at indicated times after the injection of either anti-IGFBP7
sdAb-targeted or non-targeted-NPs-Cy5.5. (D) Graph illustrating the total fluorescence concentration per gram tissue in organs imaged ex vivo 72h after the
injection of either anti-IGFBP7 sdAb-targeted or non-targeted-NPs-Cy5.5. In C and D, data are expressed as mean±s.e.m. for n¼5 animals. **Indicates
significant difference between anti-IGFBP7 sdAb-NP-Cy5.5 and non-targeted-NP-Cy5.5 (Po0.001). *Indicates significant difference between the anti-
IGFBP7 sdAb-NP-Cy5.5 and non-targeted-NP-Cy5.5 (Po0.01).
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sbetter prognosis, with a median survival ranging from 4–16.7
years depending on the age and histology of the patient (Olson
et al, 2000). However, malignant transformation is always a risk
for low-grade tumours, such that 13–86% of tumours initially
diagnosed as low grade recur at a higher histological grade (Barker
et al, 1997). The malignancy of the tumour is highly correlated to
the degree of angiogenesis (Daumas-Duport et al, 1997a,b) and the
progression from low to higher tumour grades is commonly
referred to as an ‘angiogenic switch’ (Moserle et al, 2009). It is
reasonable to argue that treatments should be applied early, either
when the angiogenic switch occurs or to prevent the angiogenic
switch from happening in the first place. To achieve information
on such a switch, however, there is a need for accurate markers of
tumour angiogenesis. As lower-grade glioma tissue sections do not
express IGFBP7 (D Stanimirovic, unpublished observations), anti-
IGFBP7 sdAb may feasibly represent a useful follow-up molecular
imaging tool in determining when the ‘angiogenic switch’ has been
turned on for low-grade gliomas. By providing information on the
degree of tumour angiogenesis and related clinical aggressiveness,
the anti-IGFBP7 sdAb could also be used to assess/monitor efficacy
of anti-angiogenic or other anti-tumour treatments, and thus
improve the clinical management of brain tumours. The high
expression and accessible nature of the IGFBP7 target in GBM
vessels, combined with virtually non-existent expression in normal
vessels, in combination with demonstrated versatility and good
in vivo targeting characteristics of anti-IGFBP7 sdAb, indicate that
linking of this antibody to the appropriate optical, PET or MRI
contrast agents could enable in vivo imaging assessment of the
degree of angiogenesis in gliomas.
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